These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9502429)

  • 21. Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53.
    Rubinstein M; Idelman G; Plymate SR; Narla G; Friedman SL; Werner H
    Endocrinology; 2004 Aug; 145(8):3769-77. PubMed ID: 15131018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
    Huang Y; Tan M; Gosink M; Wang KK; Sun Y
    Cancer Res; 2002 May; 62(10):2913-22. PubMed ID: 12019172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential activation of IGF-II promoters P3 and P4 in Caco-2 cells during growth and differentiation.
    Singh P; Dai B; Given RL; Lu X; Holthuizen PE
    Gastroenterology; 1998 Jun; 114(6):1221-9. PubMed ID: 9609759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells.
    Xu D; Wang Q; Gruber A; Björkholm M; Chen Z; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
    Oncogene; 2000 Oct; 19(45):5123-33. PubMed ID: 11064449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites.
    Lee S; Park U; Lee YI
    Virology; 2001 May; 283(2):167-77. PubMed ID: 11336542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the IGF system and analysis of the possible molecular mechanisms leading to IGF-II overexpression in a mesothelioma.
    Hodzic D; Delacroix L; Willemsen P; Bensbaho K; Collette J; Broux R; Lefèbvre P; Legros JJ; Grooteclaes M; Winkler R
    Horm Metab Res; 1997 Nov; 29(11):549-55. PubMed ID: 9479554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
    Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
    Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter.
    Pietrzak M; Puzianowska-Kuznicka M
    Biol Chem; 2008 Apr; 389(4):383-93. PubMed ID: 18208354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer.
    Webster NJ; Resnik JL; Reichart DB; Strauss B; Haas M; Seely BL
    Cancer Res; 1996 Jun; 56(12):2781-8. PubMed ID: 8665514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1.
    Ohlsson C; Kley N; Werner H; LeRoith D
    Endocrinology; 1998 Mar; 139(3):1101-7. PubMed ID: 9492043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diminished G1 checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression.
    Zhang L; Kim M; Choi YH; Goemans B; Yeung C; Hu Z; Zhan S; Seth P; Helman LJ
    J Biol Chem; 1999 May; 274(19):13118-26. PubMed ID: 10224065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: developmental relationships of the four promoters.
    Li X; Cui H; Sandstedt B; Nordlinder H; Larsson E; Ekström TJ
    J Endocrinol; 1996 Apr; 149(1):117-24. PubMed ID: 8676043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of erythrocyte protein 4.2 gene expression during differentiation of murine erythroleukemia cells.
    Karacay B; Chang LS
    Genomics; 1999 Jul; 59(1):6-17. PubMed ID: 10395794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
    Liu J; Zhan M; Hannay JA; Das P; Bolshakov SV; Kotilingam D; Yu D; Lazar AF; Pollock RE; Lev D
    Mol Cancer Res; 2006 Nov; 4(11):803-10. PubMed ID: 17077165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of insulin-like growth factor II (IGFII) in ZR-75-1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression.
    Abdul-Wahab K; Corcoran D; Perachiotti A; Darbre PD
    Cell Prolif; 1999 Oct; 32(5):271-87. PubMed ID: 10619489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogene-induced up-regulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C-mediated pathway.
    Cadoret A; Baron-Delage S; Bertrand F; Kornprost M; Groyer A; Gespach C; Capeau J; Cherqui G
    Oncogene; 1998 Aug; 17(7):877-87. PubMed ID: 9780004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells.
    Tsubaki J; Hwa V; Twigg SM; Rosenfeld RG
    Endocrinology; 2002 May; 143(5):1778-88. PubMed ID: 11956160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.
    Tang SH; Yang DH; Huang W; Zhou HK; Lu XH; Ye G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4171-7. PubMed ID: 16857788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elements required for activation of the major promoter of the human insulin-like growth factor II gene.
    van Dijk MA; Holthuizen PE; Sussenbach JS
    Mol Cell Endocrinol; 1992 Oct; 88(1-3):175-85. PubMed ID: 1334009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways.
    Sheikh MS; Li XS; Chen JC; Shao ZM; Ordonez JV; Fontana JA
    Oncogene; 1994 Dec; 9(12):3407-15. PubMed ID: 7970699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.